BMY Bristol-Myers Squibb Company
Research report · from SEC EDGAR · close 2026-07-13
$59.34 +3.1%
$121.18B mkt cap
executive summary
Bristol-Myers Squibb Company (BMY) is a $121.18B company. Revenue is $48.19B (-0.2% y/y) at a 15% net margin. It is profitable. Our health score is B (84/100). No major red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$48.19B
-0.2% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 1
Cash & ST investments
$9.57B
Operating cash flow
$14.16B
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.